Skip to main content
SpringerLink
Log in

Vilazodone and Depressions

  • Living reference work entry
  • First Online:
NeuroPsychopharmacotherapy

  • 26 Accesses

Abstract

Vilazodone is an antidepressant, which enhances the serotonin concentration in the synapse and also is a partial agonist for 5-HT1A-receptors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Croft HA, Pomara N, Gommoll C, Chen D, Nunez R, Mathews M. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2014;75(11):e1291–8.

    Article  Google Scholar 

  • Cruz MP. Vilazodone HCl (Viibryd): a serotonin partial agonist and reuptake inhibitor for the treatment of major depressive disorder. P T. 2012;37(1):28–31.

    PubMed  PubMed Central  Google Scholar 

  • Heinrich T, Böttcher H, Gericke R, Bartoszyk GD, Anzali S, Seyfried CA, Greiner HE, van Amsterdam C. Synthesis and structure–activity relationship in a class of indolebutylpiperazines as dual 5-HT1A receptor agonists and serotonin reuptake inhibitors. J Med Chem. 2004;47:4684–92. https://doi.org/10.1021/jm040793q.

    Article  PubMed  CAS  Google Scholar 

  • Howland RH. Vilazodone: another novel atypical antidepressant drug. J Psychosoc Nurs Ment Health Serv. 2011;49(3):19–22.

    Article  Google Scholar 

  • Hu F, Su W. An investigation of the synthesis of vilazodone. J Chem Res. 2019; https://doi.org/10.1177/1747519819893293.

  • Jain R, Chen D, Edwards J, Mathews M. Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials. Curr Med Res Opin. 2014;30(2):263–70.

    Article  CAS  Google Scholar 

  • Khan A, Cutler AJ, Kajdasz DK, Gallipoli S, Athanasiou M, Robinson DS, et al. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder. J Clin Psychiatry. 2011;72(4):441–7.

    Article  CAS  Google Scholar 

  • Khan A, Sambunaris A, Edwards J, Ruth A, Robinson DS. Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression. Int Clin Psychopharmacol. 2014;29(2):86–92.

    Article  Google Scholar 

  • Mathews M, Gommoll C, Chen D, Nunez R, Khan A. Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 2015;30(2):67–74.

    Article  Google Scholar 

  • Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR. Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(3):326–33.

    Article  CAS  Google Scholar 

  • Schwartz TL, Siddiqui UA, Stahl SM. Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor. Ther Adv Psychopharmacol. 2011;1(3):81–7.

    Article  CAS  Google Scholar 

  • Sorbera LA, Rabasseda X, Silvestre J, Castaner J. Vilazodone hydrochloride. Antidepressant, 5-HT1A partial agonist, 5-HT reuptake inhibitor. Drugs Future. 2001;36:247–52.

    Article  Google Scholar 

  • Traynor K. Vilazodone approved for major depression. Am J Health Syst Pharm. 2011;68(5):366.

    PubMed  Google Scholar 

  • Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU. A review of current evidence for vilazodone in major depressive disorder. Int J Psychiatry Clin Pract. 2013;17(3):160–9.

    Article  CAS  Google Scholar 

  • Zareifopoulos N, Dylja I. Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: a meta-analysis. Asian J Psychiatr. 2017;26:115–22.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Psychotherapy, University Medical Centre Rostock, Rostock, Germany

    Frank Faltraco & Johannes Thome

Authors
  1. Frank Faltraco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johannes Thome
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Johannes Thome .

Editor information

Editors and Affiliations

  1. Dept Psychiatry , Psychosomatics & Psychotherapy, University of Würzburg, Medical School Clinical Neurochemistry, Würzburg, Germany

    Peter Riederer

  2. Inst für Psychologische Medizin, Haag, Bayern, Germany

    Gerd Laux

  3. Fujita Health University School Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

  4. Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China

    Weidong Le

  5. Würzburg, Bayern, Germany

    Christian Riederer

Section Editor information

  1. Institute of Psychological Medicine (IPM), Soyen, Germany

    Gerd Laux Dipl.-Psych.

  2. Department of Psychiatry, Ludwig-Maximilians-University Munich, Munich, Germany

    Hans-Jürgen Möller

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Faltraco, F., Thome, J. (2022). Vilazodone and Depressions. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_113-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56015-1_113-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56015-1

  • Online ISBN: 978-3-319-56015-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation